RV
Ravi V. Vij
Highly rated in
24
conditions

Dr. Ravi V. Vij

Center For Advanced Medicine
Saint Louis, MO
Highly rated in
24
conditions
Specialties:Oncology | Hematology
Experience:32 Years
Age:56
Clinical Trials:Currently Recruiting for 12 Trials
Accepts:New PatientsMedicare
Highly rated in
24
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

View 28 More Conditions +
Check Dr. Ravi V. Vij's experience treating your condition:
About Dr. Ravi V. Vij

Ravi Vij is an Oncologist and a Hematologist in Saint Louis, Missouri. Vij has been practicing medicine for over 32 years and is highly rated in 24 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Missouri. Vij is currently accepting new patients.

His clinical research consists of co-authoring 244 peer reviewed articles and participating in 49 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Ravi V. Vij it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Ravi V. Vij accepts the following insurance:

  •  Ambetter
  •  Cigna
  •  Cox Health
Call to see if your plan is accepted.
Locations
4921 Parkview Pl, Suite 7b, Saint Louis, MO 63110
Other Locations
1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110
Background & Education
Graduate Institution
Other, 1991
Specialties
Oncology
Hematology
Licenses
Internal Medicine in MO
Hospital Affiliations
Barnes-Jewish Hospital
Barnes-Jewish St Peters Hospital
Barnes-Jewish West County Hospital
Christian Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

49 Clinical Trials
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant in Children and Adults
Enrollment Status: Recruiting
Publish Date: October 31, 2022
Intervention Type: Procedure, Drug
Study Drug: CIML NK Cell Infusion
Study Phase: Phase 1/Phase 2
A Phase Ib Study of Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
Enrollment Status: Recruiting
Publish Date: September 28, 2022
Intervention Type: Drug
Study Drugs: IsatuximabBortezomibDexamethasone
Study Phase: Phase 1
A Phase I/II Trial of Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma
Enrollment Status: Recruiting
Publish Date: September 22, 2022
Intervention Type: Drug, Biological
Study Drugs: IsatuximabBendamustinePrednisone
Study Phase: Phase 1/Phase 2
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Enrollment Status: Recruiting
Publish Date: September 01, 2022
Intervention Type: Procedure, Drug, Device
Study Phase: Phase 2
A Single-Arm, Open-Label, Pilot Study and Expansion Study of JAK Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Enrollment Status: Recruiting
Publish Date: August 24, 2022
Intervention Type: Other, Drug, Procedure
Study Drug: Itacitinib
Study Phase: Phase 1
Identification of AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
Enrollment Status: Recruiting
Publish Date: August 12, 2022
Intervention Type: Procedure
A Phase II Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
Enrollment Status: Recruiting
Publish Date: August 09, 2022
Intervention Type: Procedure, Drug
Study Drugs: TacrolimusMycophenolate mofetilG-CSFALT-803
Study Phase: Phase 2
Real World Observational Study Using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry
Enrollment Status: Recruiting
Publish Date: August 04, 2022
Intervention Type: Diagnostic Test
Early Phase I Evaluation of 64Cu-LLP2A for Imaging Multiple Myeloma
Enrollment Status: Recruiting
Publish Date: July 28, 2022
Intervention Type: Procedure, Device, Drug
Study Drug: 64Cu-LLP2A
Study Phase: Early Phase 1
Phase II Trial With Safety Lead in of Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Enrollment Status: Recruiting
Publish Date: July 19, 2022
Intervention Type: Drug, Procedure
Study Drug: Duvelisib
Study Phase: Phase 2
A Phase I Study of ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
Enrollment Status: Recruiting
Publish Date: July 13, 2022
Intervention Type: Drug
Study Drug: ApoGraft
Study Phase: Phase 1
Analysis of Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Enrollment Status: Recruiting
Publish Date: June 01, 2022
Intervention Type: Procedure
A Single-Arm, Open-Label Phase I Clinical Trial of a JAK Inhibitor, Baricitinib, for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
Enrollment Status: Active, not recruiting
Publish Date: December 12, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 1
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active, not recruiting
Publish Date: November 10, 2022
Intervention Type: Drug, Biological
Study Drugs: IxazomibLenalidomideDexamethasone
Study Phase: Phase 2
A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Enrollment Status: Active, not recruiting
Publish Date: October 18, 2022
Intervention Type: Drug
Study Drugs: ElotuzumabPomalidomideDexamethasone
Study Phase: Phase 2
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Enrollment Status: Completed
Publish Date: August 04, 2022
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Anti-Thymocyte GlobulinAzacitidineBusulfanFludarabineMethotrexateTacrolimus
Study Phase: Phase 2
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed AML
Enrollment Status: Not yet recruiting
Publish Date: July 01, 2022
Intervention Type: Drug, Procedure, Biological
Study Drugs: Cytokine induced memory-like NK cellsFludarabineAra-CG-CSFInterleukin-2
Study Phase: Phase 2
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
Enrollment Status: Active, not recruiting
Publish Date: May 25, 2022
Intervention Type: Biological
Study Drug: CYNK-001
Study Phase: Phase 1
A Phase 1/2 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS
Enrollment Status: Active, not recruiting
Publish Date: April 15, 2022
Intervention Type: Procedure, Biological, Drug
Study Drugs: FludarabineCyclophosphamideALT-803Cytokine-Induced Natural Killer T CellsIL-2
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Enrollment Status: Withdrawn
Publish Date: March 11, 2022
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 2
ESCALADARA: Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma
Enrollment Status: Withdrawn
Publish Date: January 24, 2022
Intervention Type: Biological, Procedure
Study Drug: Dara-SC
Study Phase: Phase 2
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Enrollment Status: Active, not recruiting
Publish Date: January 13, 2022
Intervention Type: Drug, Procedure
Study Drugs: Anti-thymocyte globulinSolumedrolTacrolimusMycophenolate mofetil
Study Phase: Phase 2
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: February 04, 2021
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
Enrollment Status: Completed
Publish Date: November 20, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Study of Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Enrollment Status: Terminated
Publish Date: October 20, 2020
Intervention Type: Radiation, Drug, Procedure
Study Phase: Phase 1
An Investigator Sponsored Phase I/II Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Procedure, Drug
Study Phase: Phase 1/Phase 2
A Pilot Study of CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: December 05, 2019
Intervention Type: Procedure, Drug
Study Phase: Phase 1
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: November 26, 2019
Intervention Type: Procedure, Drug
Study Phase: Phase 2
Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: October 16, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: April 08, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase 1 Study of Daratumumab When Given in Combination With Bortezomib, Dexamethasone, Doxil, and Lenalidomide in Patients With Plasma Cell Leukemia
Enrollment Status: Withdrawn
Publish Date: December 19, 2018
Intervention Type: Drug, Biological
Study Phase: Phase 1
A Pilot Study of Myeloablative Allogeneic or Haploidentical Stem Cell Transplantation With High Dose PT-Cy in Relapsed/Refractory AML
Enrollment Status: Terminated
Publish Date: October 12, 2018
Intervention Type: Radiation, Drug, Procedure
Study Phase: Phase 1
A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects With Lymphoid Hematological Malignancies
Enrollment Status: Terminated
Publish Date: February 27, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
Enrollment Status: Completed
Publish Date: January 08, 2018
Intervention Type: Biological, Drug
Study Phase: Phase 1
A Pilot Study of Pacritinib in Combination With Low Dose Decitabine in Patients With Intermediate-High Risk Myelofibrosis or MPN/MDS Syndromes
Enrollment Status: Withdrawn
Publish Date: May 08, 2017
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes
Enrollment Status: Completed
Publish Date: December 12, 2016
Intervention Type: Drug
Study Phase: Phase 2
A Phase I Trial of Carfilzomib in Adult Patients With Relapsed Acute Myeloid and Acute Lymphoblastic Leukemia
Enrollment Status: Completed
Publish Date: June 14, 2016
Intervention Type: Drug
Study Phase: Phase 1
Phase II Trial of High Dose Lenalidomide in Patients With Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Enrollment Status: Completed
Publish Date: January 05, 2016
Intervention Type: Drug
Study Phase: Phase 2
Phase I/II Trial of Azacitidine Plus Lenalidomide in the Treatment of Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: September 07, 2015
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Pilot Study of G-CSF to Disrupt the Bone Marrow Microenvironment in Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: January 26, 2015
Intervention Type: Drug
Study Phase: Early Phase 1
A Phase II Study of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) as Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation for Multiple Myeloma
Enrollment Status: Terminated
Publish Date: October 15, 2014
Intervention Type: Drug, Procedure
Study Phase: Phase 2
Phase II Trial of Lenalidomide in Older Patients (>/= 60 Years) With Untreated Acute Myeloid Leukemia Without Chromosome 5q Abnormalities
Enrollment Status: Completed
Publish Date: September 29, 2014
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of PTK787/ZK 222584, a Novel, Oral Angiogenesis Inhibitor as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma Following High Dose Chemotherapy and Autologous Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: September 17, 2014
Intervention Type: Drug
Study Phase: Phase 2
A Non-Myeloablative Conditioning Regimen for Allogeneic Transplantation With Clofarabine, Cytarabine, and Thymoglobulin for Myelodysplastic Syndrome and Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: September 12, 2014
Intervention Type: Drug, Procedure
Study Phase: Phase 2
A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma
Enrollment Status: Completed
Publish Date: August 29, 2014
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: August 13, 2013
Intervention Type: Drug
Study Phase: Phase 2
Randomized Trial of Preemptive Treatment With Oral Valganciclovir Compared With IV Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: July 23, 2013
Intervention Type: Drug
Study Phase: Phase 3
A Phase I Study of Intravenous Decitabine in Combination With Arsenic Trioxide and Ascorbic Acid in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: June 04, 2013
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: April 23, 2013
Intervention Type: Drug
Study Phase: Phase 1
View 37 Less Clinical Trials -
244 Total Publications
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 27, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
IP
Dr. Iskra Pusic
Oncology | Hematology
Highly rated in
19
conditions
Oncology
Hematology

BJC HealthCare

Center For Advanced Medicine

4921 Parkview Pl, 
Saint Louis, MO 

Iskra Pusic is an Oncologist and a Hematologist in Saint Louis, Missouri. Pusic has been practicing medicine for over 26 years and is highly rated in 19 conditions, according to our data. Her top areas of expertise are Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. She is licensed to treat patients in Missouri. Pusic is currently accepting new patients.

BV
Dr. Brian A. Van Tine
Oncology
Highly rated in
38
conditions
Oncology

BJC HealthCare

Siteman Cancer Center

4921 Parkview Pl, 
Saint Louis, MO 

Brian Van Tine is an Oncologist in Saint Louis, Missouri. Van Tine has been practicing medicine for over 18 years and is highly rated in 38 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Synovial Sarcoma, Liposarcoma, Epithelioid Sarcoma, and Vertebroplasty. He is licensed to treat patients in Missouri. Van Tine is currently accepting new patients.

RG
Dr. Ramaswamy B. Govindan
Oncology | Hematology Oncology
Highly rated in
21
conditions
Oncology
Hematology Oncology

BJC HealthCare

Center For Advanced Medicine

4921 Parkview Pl, 
Saint Louis, MO 

Ramaswamy Govindan is an Oncologist and a Hematologist Oncology expert in Saint Louis, Missouri. Govindan has been practicing medicine for over 37 years and is highly rated in 21 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NCSLC), Lung Cancer, Small Cell Lung Cancer (SCLC), Squamous Cell Lung Carcinoma, and Tissue Biopsy. He is licensed to treat patients in Missouri. Govindan is currently accepting new patients.